Fundamental research is the basis for understanding and treatment of many human diseases

FEBS Letters

Volumn 580, Issue 23, 2006, Pages 5430-5435

  Vance, Dennis E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cholesterol; Fabry disease; Glycosphingolipids; Heart disease; Liver disease; Muscular dystrophy; Phosphatidylcholine; Sphingolipids

Indexed keywords

PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; ENZYME DEGRADATION; FABRY DISEASE; HUMAN; INCIDENCE; LIPID ANALYSIS; LIPID METABOLISM; LIVER DISEASE; MEDICAL RESEARCH; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FABRY DISEASE; HUMANS; MICROARRAY ANALYSIS; PHOSPHATIDYLCHOLINES; RESEARCH;

EID: 33749060439     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.06.025     Document Type: Short Survey

References (51)

1. Desnick R.J., Ioannou Y.A., and Eng C.M. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic Basis of Inherited Disease (1995), McGraw-Hill, Inc, New York 2741-2784
2. Bentley R., Sweeley C.C., Makita M., and Wells W.W. Gas chromatography of sugars and other polyhydroxy compounds. Biochem. Biophys. Res. Commun. 11 (1963) 14-18
3. Sweeley C.C., and Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol. Chem. 238 (1963) 3148-3150
4. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl. J. Med. 276 (1967) 1163-1167
5. Bishop D.F., Calhoun D.H., Bernstein H.S., Hantzopoulos P., Quinn M., and Desnick R.J. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc. Natl. Acad. Sci. USA 83 (1986) 4859-4863
6. Kornreich R., Desnick R.J., and Bishop D.F. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 17 (1989) 3301-3302
7. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., Sugimoto Y., Pastan I., Gottesman M.M., Brady R.O., et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA 94 (1997) 2540-2544
8. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97 (2000) 365-370
9. Desnick R.J. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin. Biol. Ther. 4 (2004) 1167-1176
10. Takenaka T., Murray G.J., Qin G., Quirk J.M., Ohshima T., Qasba P., Clark K., Kulkarni A.B., Brady R.O., and Medin J.A. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Natl. Acad. Sci. USA 97 (2000) 7515-7520
11. Abe A., Gregory S., Lee L., Killen P.D., Brady R.O., Kulkarni A., and Shayman J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 105 (2000) 1563-1571
12. Vance D.E., and Van den Bosch H. Cholesterol in the year 2000. Biochim. Biophys. Acta 1529 (2000) 1-8
13. Gibbons G.F., Mitropoulos K.A., and Myant N.B. Biochemistry of Cholesterol (1982), Elsevier Biomedical Press, Amsterdam 369pp
14. Schoenheimer R., and Breusch F. Synthesis and destruction of cholesterol in the organism. J. Biol. Chem. 103 (1933) 439-448
15. Gould R.G. Lipid metabolism and atherosclerosis. Am. J. Med. 11 (1951) 209-227
16. Gould R.G., Taylor C.B., Hagerman J.S., Warner I., and Campbell D.J. Cholesterol metabolism. I. Effect of dietary cholesterol on the synthesis of cholesterol in dog tissue in vitro. J. Biol. Chem. 201 (1953) 519-528
17. Engelking L.J., Liang G., Hammer R.E., Takaishi K., Kuriyama H., Evers B.M., Li W.P., Horton J.D., Goldstein J.L., and Brown M.S. Schoenheimer effect explained-feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J. Clin. Invest. 115 (2005) 2489-2498
18. Anderson R.G. Joe Goldstein and Mike Brown: from cholesterol homeostasis to new paradigms in membrane biology. Trends Cell Biol. 13 (2003) 534-539
19. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res. 46 (2005) 179-190
20. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J. Lipid Res. 45 (2004) 1583-1593
21. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46 (2005) 2037-2051
22. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it - almost. J. Lipid Res. 47 (2006) 1-14
23. Steinberg, D., 2006. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J Lipid Res.
24. Endo A., Kuroda M., and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 29 (1976) 1346-1348
25. Endo A., Kuroda M., and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72 (1976) 323-326
26. Brown M.S., Faust J.R., Goldstein J.L., Kaneko I., and Endo A. Induction of 3-hydroxy-3- methylglutaryl-CoA reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. (1978) 253
27. Best C.H., and Huntsman M.E. The effects of the components of lecithin upon deposition of fat in the liver. J. Physiol. - London 75 (1932) 405-412
28. Wittenberg J., and Kornberg A. Choline phosphokinase. J. Biol. Chem. 202 (1953) 431-444
29. Kennedy E.P. Discovery of the pathways for the biosynthesis of phosphatidylcholine. In: Vance D.E. (Ed). Phosphatidylcholine Metabolism (1989), CRC Press, Boca Raton 1-9
30. Kennedy E.P., and Weiss S.B. The function of cytidine coenzymes in the biosynthesis of phospholipids. J. Biol. Chem. 222 (1956) 193-214
31. Vance D.E. Boehringer Mannheim Award lecture. Phosphatidylcholine metabolism: masochistic enzymology, metabolic regulation, and lipoprotein assembly. Biochem. Cell Biol. 68 (1990) 1151-1165
32. Sundler R., and Akesson B. Regulation of phospholipid biosynthesis in isolated rat hepatocytes. Effect of different substrates. J. Biol. Chem. 250 (1975) 3359-3367
33. Vance D.E., and Choy P.C. How is phosphatidylcholine biosynthesis regulated?. Trends Biochem. Sci. 4 (1979) 145-148
34. Kent C. Stimulation of phospholipid metabolism in embryonic muscle cells treated with phospholipase C. Proc. Natl. Acad. Sci. USA 76 (1979) 4474-4478
35. Pelech S.L., and Vance D.E. Regulation of phosphatidylcholine biosynthesis. Biochim. Biophys. Acta 779 (1984) 217-251
36. Vance D.E. Phospholipid biosynthesis in eukaryotes. In: Vance D.E., and Vance J.E. (Eds). Biochemistry of Lipids, Lipoproteins and Membranes (2002), Elsevier Science, Amsterdam 205-232
37. Cornell R.B., and Northwood I.C. Regulation of CTP:phosphocholine cytidylyltransferase by amphitropism and relocalization. Trends Biochem. Sci. 25 (2000) 441-447
38. Jackowski S., and Fagone P. CTP:phosphocholine cytidylyltransferase: paving the way from gene to membrane. J. Biol. Chem. 280 (2005) 853-856
39. Kent C. CTP:phosphocholine cytidylyltransferase. Biochim. Biophys. Acta 1348 (1997) 79-90
40. Wang Y., Sweizer T.D., Weinhold P.A., and Kent C. Nuclear localization of soluble CTP:phosphocholine cytidylyltransferase. J. Biol. Chem. 268 (1993) 5899-5904
41. Sher R.B., Aoyama C., Huebsch K.A., Ji S., Kerner J., Yang Y., Frankel W.N., Hoppel C.L., Wood P.A., Vance D.E., et al. A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 281 (2006) 4938-4948
42. Bremer J., and Greenberg D.M. Methyltransfering enzyme system of microsomes in the biosynthesis of lecithin (phosphatidylcholine). Biochim. Biophys. Acta 46 (1961) 205-216
43. Ridgway N.D., and Vance D.E. Purification of phosphatidylethanolamine N-methyltransferase from rat liver. J. Biol. Chem. 262 (1987) 17231-17239
44. Cui Z., Vance J.E., Chen M.H., Voelker D.R., and Vance D.E. Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. J. Biol. Chem. 268 (1993) 16655-16663
45. Walkey C.J., Donohue L.R., Bronson R., Agellon L.B., and Vance D.E. Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc. Natl. Acad. Sci. USA 94 (1997) 12880-12885
46. Walkey C.J., Yu L., Agellon L.B., and Vance D.E. Biochemical and evolutionary significance of phospholipid methylation. J. Biol. Chem. 273 (1998) 27043-27046
47. Esko J.D., Nishijima M., and Raetz C.R.H. Animal cells dependent on exogenous phosphatidylcholine for membrane biogenesis. Proc. Natl. Acad. Sci. USA 79 (1982) 1698-1702
48. Cui Z., Houweling M., Chen M.H., Record M., Chap H., Vance D.E., and Terce F. A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. J. Biol. Chem. 271 (1996) 14668-14671
49. Li Z., Agellon L.B., and Vance D.E. Phosphatidylcholine homeostasis and liver failure. J. Biol. Chem. 280 (2005) 37798-37802
50. Li Z., Agellon L.B., Allen T.M., Umeda M., Jewell L., Mason A., and Vance D.E. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3 (2006) 321-331
51. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004) 147-152